- Policy
- Academia requests reimb expansion for Perjeta, Verzenio
- by Lee, Tak-Sun Nov 25, 2024 05:53am
- Lymph node-positive patients will now be reimbursed for their use of the breast cancer drug Perjeta inj (pertuzumab, Roche).&160; The reimbursement extension was requested by the relevant medical societies and will take effect in December. It is interesting to note that the new criteria for reimbursement of anticancer drugs were establish
- Policy
- Korea’s 2nd GIFT drug Nefecon is approved in KOR
- by Lee, Hye-Kyung Nov 22, 2024 05:55am
- Meditip's Nefecon (budesonide), which was designated as the 2nd Global Innovative Products on Fast Track (GIFT) drug, has been approved in Korea. The Ministry of Food and Drug Safety approved Nefecon on the 18th. Nefecon is used to treat primary IgA nephropathy in adults with a urinary protein-to-creatinine ratio of 1.5 or greater who
- Policy
- CKD drug Kerendia seeks indication expansion in KOR
- by Lee, Hye-Kyung Nov 21, 2024 05:46am
- Bayer Korea's Kerendia (finerenone), which is used to treat adult patients with chronic kidney disease with type 2 diabetes, will enter Phase III clinical trials in Korea to expand its indication. On the 20th, the Ministry of Food and Drug Safety (MFDS), approved a ‘randomized clinical trial to determine the efficacy and safety of finere
- Policy
- Strengthed regulations on human drug use in vet clinics
- by Lee, Jeong-Hwan Nov 20, 2024 06:08am
- A bill that requires frontline pharmacies to record detailed distribution details on human specialty drugs sold to veterinary hospitals has passed the Bill Review Subcommittee review. Although there was a lot of disagreement over the bill between the professions subject to the regulation - the pharmacists and the veterinarians - the Healt
- Policy
- Stelara biosimilars face increasing competition
- by Lee, Tak-Sun Nov 20, 2024 06:08am
- Competition among biosimilars referencing Stelara (ustekinumab) for treating autoimmune diseases heats up. Samsung Bioepis added its biosimilar to the reimbursement list in July, and Celltrion added theirs in September. Since Celltrion is set to cut the price starting next month, attention has been drawn to future competition. According
- Policy
- Samil voluntarily cuts price of its Vemlino to lowest price
- by Lee, Tak-Sun Nov 19, 2024 06:13am
- Samil Pharm is voluntarily reducing the price of its hepatitis B drug Vemlino (Tenofovir Alafenamide Hemimalate). This will render the drug to be the lowest-priced drug among tenofovir alafenamide drugs, increasing its price competitiveness. According to industry sources on the 18th, the price of Vemlino will be reduced from KRW 2,425 t
- Policy
- HK Inno.N to distribute Tamiflu as Roche’s new partner
- by Lee, Tak-Sun Nov 18, 2024 05:49am
- HK Inno.N will be responsible for the domestic distribution of ‘Tamiflu Cap’ in addition to the distribution of the antiviral drug ‘Xofluza.’ The company is expected to gain external growth with the distribution of Tamiflu, which has an annual sales volume of KRW 15 billion. According to industry sources on the 15th, HK Inno.N se
- Policy
- AZ’s Imjudo and Imfinzi both make reimbursement progress
- by Lee, Tak-Sun Nov 15, 2024 05:49am
- AstraZeneca (AZ) Korea’s ‘Imjudo Inj.’ Has passed the first step to reimbursement listing in Korea. Also, reimbursement standards for ‘Imfinzi Inj,’ which is seeking reimbursement expansions, were set. However, these are only the first steps to reimbursement. On the 13th, the Health Insurance Review and Assessment Service held the 8th
- Policy
- NHIS-Roche enters pricing negotiations for Perjeta’s reimb
- by Lee, Tak-Sun Nov 12, 2024 05:50am
- Roche has started drug price negotiations with the National Health Insurance Service for its breast cancer drug Perjeta (pertuzumab). The negotiations are expected to be held on the drugs whose reimbursement standards were set by the Cancer Disease Review Committee in May. According to industry sources on the 11th, the NHIS recently inc
- Policy
- Drug switching for atopic dermatitis measure submitted
- by Lee, Tak-Sun Nov 7, 2024 05:47am
- Discussions about allowing drug switching between biological agents and JAK inhibitors used to treat severe atopic dermatitis are speeding up. The Health Insurance Review and Assessment Service (HIRA) has already prepared the reimbursement criteria, and pharmaceutical companies have submitted their measures for voluntary drug price redu
